Full Report

The numbers behind Doximity, Inc.: as-reported financial statements and company metrics for FY2022–FY2026, traced to the source filings, opened with the share-price history those statements have to justify. Every linked figure opens the exact page of the filing it was printed on, with the statement row highlighted. Amounts in US$ thousands unless noted.

Reading notes: All figures are as printed in Doximity's Form 10-K filings, in thousands of US dollars (except per-share and share-count data), fiscal year ended March 31. Revenue breakdown (subscription vs. other service revenue) is Doximity's own reported disaggregation from Note 3, Revenue Recognition — the company reports a single operating segment. FY2020 and FY2021 income-statement, cash-flow and per-share figures in the Long-Term Record are comparative columns of the FY2022 Form 10-K (physical p.110 income, p.114 cash flow). FY2020 total stockholders' equity is not printed in the corpus and is shown unlinked (null). Each core-statement year links to that year's own Form 10-K (first data column), so every citation anchor is the primary reporting period.

Share Price — Full Available History — 5 Years

The stock closed at $21.77 on Jul 10, 2026 — down 59% over the window shown (-16.2% a year), trading between $18.01 and $102.02. At that close the stock trades at 22× FY2026 diluted EPS as reported below.

Source: market price feed, weekly closes, sampled from 1,266 source observations, Jun 2021–Jul 2026. Price return only, excludes dividends.

FY2026 at a Glance

Source: FY2026 consolidated statements [1] [2] [3] [4]. Click any linked figure to open the filing page with the row highlighted.

Revenue by Type

Revenue by Type	FY2022	FY2023	FY2024	FY2025	FY2026
Subscription	319,298	389,739	450,071	543,770	608,413
Other	24,250	29,313	25,351	26,629	36,450
Total revenue	343,548	419,052	475,422	570,399	644,863
Total revenue growth, derived	—	+22.0%	+13.5%	+20.0%	+13.1%

Source: Note 3 Revenue Recognition — Revenue Disaggregation (subscription vs. other service revenue) [5] [6] [7] [8]. Click any linked figure to open the filing page with the row highlighted.

Income Statement

Source: Consolidated Statements of Operations [1] [2] [3] [4]. Click any linked figure to open the filing page with the row highlighted.

Columns marked E are consensus analyst estimates shown alongside reported results for direct comparison; they are not company guidance.

Estimate source: Yahoo Finance analyst consensus, as of 2026-07-12. Estimate figures link to the consensus source, not to filing pages.

Balance Sheet

Source: Consolidated Balance Sheets [9] [10] [11] [12]. Click any linked figure to open the filing page with the row highlighted.

Cash Flow

Source: Consolidated Statements of Cash Flows [13] [14] [15] [16]. Click any linked figure to open the filing page with the row highlighted.

Long-Term Record

Fiscal year	Total revenue	Income from operations	Net income	Diluted net income per share	Operating cash flow	Total stockholders' equity
FY2020	116,388	22,163	29,737	0.13	26,199	—
FY2021	206,897	53,303	50,210	0.23	82,973	66,743
FY2022	343,548	113,536	154,783	0.70	126,575	878,594
FY2023	419,052	125,108	112,818	0.53	179,602	966,116
FY2024	475,422	163,878	147,582	0.72	184,096	901,397
FY2025	570,399	227,800	223,185	1.11	273,265	1,082,625
FY2026	644,863	214,920	196,051	0.98	326,458	950,837

Source: consolidated statements across filings; older years from the standardized feed [13] [1] [9] [14]. Click any linked figure to open the filing page with the row highlighted.

Operating KPIs

KPI	FY2022	FY2023	FY2024	FY2025	FY2026
Customers with trailing 12-month subscription revenue over $500,000	—	—	100	118	125
Net revenue retention rate	—	—	114.0%	119.0%	109.0%
Quarterly unique active providers using Workflow Tools	—	—	580,000	620,000	810,000

Source: company-reported operating metrics [17] [18]. Click any linked figure to open the filing page with the row highlighted.

Analyst Consensus

Estimate source: Yahoo Finance analyst consensus, as of 2026-07-12. Estimate figures link to the consensus source, not to filing pages.

Traceability

327 of 327 figures on this page (100%) link to the filing page where they are printed — click a linked figure to open the source PDF at that page with the row highlighted. Unlinked figures come from standardized data feeds or pre-filing years.

• All figures are as printed in Doximity's Form 10-K filings, in thousands of US dollars (except per-share and share-count data), fiscal year ended March 31.

• Revenue breakdown (subscription vs. other service revenue) is Doximity's own reported disaggregation from Note 3, Revenue Recognition — the company reports a single operating segment.

• FY2020 and FY2021 income-statement, cash-flow and per-share figures in the Long-Term Record are comparative columns of the FY2022 Form 10-K (physical p.110 income, p.114 cash flow). FY2020 total stockholders' equity is not printed in the corpus and is shown unlinked (null).

• Each core-statement year links to that year's own Form 10-K (first data column), so every citation anchor is the primary reporting period.

• Quarterly cash flow: single quarters are derived from the printed year-to-date 10-Q statements (see the statement note); each derived value reconciles exactly to data/financials/cash_flow_quarterly.json. Q4 (fiscal-year-end) quarters are omitted from the quarterly block because no 10-Q prints them; the full year appears in the annual statements.

• No stock splits occurred over the covered periods; per-share figures are on the as-reported basis (eps_split_adjusted=false).

• 1 figure(s) differed between the data feed and the filing; the filing value is shown (see the run's metrics/metrics_tab.json for the audit trail).

---

Platform and Price

Doximity runs the dominant professional network for U.S. physicians and rents access to that audience to drug makers and hospitals. The economics are unusual: 89% gross margins, roughly half of every revenue dollar converted to free cash flow, no debt, and $749 million of net cash [1]. Yet after management guided fiscal 2027 revenue growth to about 4%, down from north of 20%, the shares have fallen roughly 70% since September 2025. This chapter sets out what the company is, how it earns, and the question that fall poses.

Sources: FY2026 revenue and 85% physician reach, FY2026 Annual Report (Form 10-K) [2] [3]; free-cash-flow margin and net cash, Q4 FY2026 earnings call [4].

What Doximity is and how it earns

Doximity describes itself as the leading digital platform for U.S. medical professionals, with more than 3 million registered members as of March 31, 2026 — over 85% of U.S. physicians across all 50 states and every specialty, two-thirds of nurse practitioners and physician assistants, and roughly 90% of graduating medical students [5]. Membership is free. The network is the asset; the customers who pay are on the other side of it.

Those paying customers are chiefly pharmaceutical manufacturers and health systems, and they buy three families of product [6]:

• Marketing Solutions — the core of the business — let drug makers and health systems deliver branded clinical content and peer connections to specific physician audiences.
• Hiring Solutions provide digital recruiting into the network of active and passive medical candidates.
• Workflow Solutions are the free clinician tools — telehealth, on-call scheduling, digital fax, and a Clinical AI Suite — that keep physicians engaged and feed the data behind the marketing product.

The model is a two-sided network: physician engagement with the free tools widens the audience, which raises the value of the paid marketing product, which funds more tools [7]. Revenue is concentrated: the 125 customers that each spent more than $500,000 in fiscal 2026 accounted for about 83% of revenue [8]. Almost all of it — $608 million of $645 million — is subscription-based [9].

The financial record

Revenue rose from $116 million in fiscal 2020 to $645 million in fiscal 2026, and free cash flow expanded alongside it every year — an unbroken record that matters more here than any single year's figure [10].

Source: FY2026 Annual Report (Form 10-K), consolidated statements of operations and cash flows; free cash flow computed as operating cash flow less capital expenditure [11]. Doximity's own definition also nets capitalized software and reports $317M of free cash flow for FY2026, 49% of revenue [12].

The cash conversion is the standout feature. Capital spending is trivial — under $2 million in most years — so operating cash flow drops almost intact to free cash flow, which reached $317 million in fiscal 2026 on the company's own definition, or 49% of revenue [13]. For an investor who weighs the consistency of free cash flow, the seven-year line is the relevant fact: it has never gone backward.

The slowdown behind the metrics

Growth has been decelerating for two years, and the two subscription metrics management publishes tell the same story. The number of large customers keeps rising, but net revenue retention — the rate at which existing customers expand — has fallen from 157% in fiscal 2022 to 109% in fiscal 2026 [14]. Above 100% still means the installed base is growing, but the pace of that expansion has roughly halved.

Source: FY2026 Annual Report (Form 10-K), Key Business and Financial Metrics; revenue growth computed from reported revenue [15].

Management's guidance made the deceleration explicit. For fiscal 2027 it expects revenue of $664–676 million — about 4% growth at the midpoint — and an adjusted EBITDA margin of 49%, down from 55%, citing a step-up in AI compute costs it plans to carry through the year [16]. The stated cause is demand, not the platform: management describes the market for digital pharmaceutical advertising to healthcare professionals as soft, with policy uncertainty elevated and visibility limited, and expects that market to grow at or below 5% this year [17]. The 10-K carries the same caution: policy and macroeconomic uncertainty may slow decision-making and reduce discretionary marketing spend at pharmaceutical companies [18].

The re-rating

The market treated the slowdown as a change in kind, not degree. From a September 2025 quarter-end close of about $73, the shares fell to roughly $22 by mid-2026 — near a five-year low, and down close to 80% from the 2021 post-IPO peak above $100.

Source: daily closing prices, NYSE: DOCS (company price feed); calendar-quarter-end closes, with the final point at 10 July 2026.

At roughly $22, the equity is worth about $4.3 billion. Strip out the $749 million of net cash and the operating business is valued near $3.6 billion — around 11 times fiscal 2026 free cash flow, or about 22 times GAAP earnings before the cash offset [19]. That is a price a slow-growth business could carry; whether it is cheap depends entirely on whether 4% is a floor or a ceiling.

Balance sheet and control

Two facts frame the risk. First, there is effectively no solvency risk: Doximity carries no debt, held $749 million in cash and marketable securities at year-end, and generates cash every quarter [20]. It has been returning that cash aggressively — $432 million of stock repurchased in fiscal 2026, up from $116 million a year earlier, with $493 million of authorization remaining [21].

Second, the company is founder-controlled. Co-founder Jeffrey Tangney held about 29.9% of the company as of May 2026 [22] and serves as chief executive and board chair; the board has no independent chair and is classified into three staggered classes [23]. The insider alignment and the concentration of control are two sides of one fact, and the governance detail — including the dual-class voting structure — warrants its own examination later in this report.

The question this report answers

Doximity is a rare combination: a network that reaches most of its market, near-90% gross margins, half of revenue in free cash flow, net cash, a founder with a large personal stake, and a share price down some 70% in ten months. The central question is whether the collapse to roughly 4% guided growth marks the structural maturing of a near-saturated physician-marketing niche, or a cyclical trough in pharmaceutical marketing budgets that leaves the post-decline price offering a genuine margin of safety. Everything that follows is an attempt to distinguish the two.

---

Moat and Rivals

Doximity's advantage is real and shows up in the numbers: it reaches more than 85% of U.S. physicians, earns an 89% gross margin, and runs a 33% GAAP operating margin — no competitor for pharmaceutical marketing budgets comes close on reach or profitability [1] [2]. The slowdown that halved the share price is showing up at those competitors too, which points more to a soft pharmaceutical-advertising cycle than to Doximity losing ground. The sharper question is a newer one: whether AI-native rivals reaching physicians directly erode the engagement the whole model rests on.

The moat, in numbers

A moat has to appear as returns, margins, retention, or pricing power, or it is only a story. Doximity's does. Its network reaches more than 85% of U.S. physicians across every specialty, roughly 90% of graduating medical students, and two-thirds of nurse practitioners and physician assistants — a position no rival approaches [3]. That reach is the input to the economics a pharmaceutical marketer actually pays for: a verified, near-complete audience of prescribers that is otherwise expensive and slow to assemble. Doximity argues the underlying data set — member interactions combined with previously siloed public records — "would be highly challenging and time-consuming for any competitor to replicate" [4].

The clearest evidence the advantage is company-specific rather than a good industry is the gap in profitability between Doximity and the companies chasing the same budgets. The corpus's designated peers were selected precisely because they compete for pharmaceutical and health-system marketing, hiring, or intelligence spend. On the most recently reported full year, Doximity earned a 33% operating margin; the nearest pure point-of-care marketing peer, OptimizeRx, is one-sixth its size and just crossed into profitability, while Definitive Healthcare — selling commercial intelligence into the same pharmaceutical budgets — is shrinking and lossmaking.

Sources: revenue and operating income as reported in each company's latest Form 10-K (Doximity FY2026 [5]; OptimizeRx, Phreesia, Definitive Healthcare figures per company filings). Definitive Healthcare's FY2025 operating margin reflects large goodwill impairments; its underlying operations run near breakeven. OptimizeRx guidance from its Q1 FY2026 call [6].

Phreesia is the one peer growing faster than Doximity with more scale, but most of its revenue is patient-intake software and payments rather than pharmaceutical marketing, so it is a partial comparison at best. The pattern that matters is the profitability gap: Doximity converts its audience into roughly $317 million of free cash flow at a 49% margin, while the companies competing for the same marketing dollars mostly operate at or below breakeven [7]. Pricing power of that magnitude is the signature of a wide moat, not a narrow one.

The slowdown is the cycle's, not Doximity's alone

The evidence for the through-line's central tension — structural maturing versus cyclical trough — is clearest when Doximity's slowdown is read against its peers rather than in isolation. Management's account is that demand, not the platform, is soft: it describes the market for digital pharmaceutical advertising to healthcare professionals as weak, with policy uncertainty elevated and macroeconomic risk rising, and expects the overall market to grow "at or below 5%" this year [8]. That framing is self-serving by nature — a slowing company prefers a cyclical story to a structural one — so it is worth testing against companies with no reason to coordinate their message.

They corroborate it. OptimizeRx, reporting for the calendar quarter that overlaps Doximity's, cut its full-year 2026 revenue guidance to $95–100 million — a decline from $109 million — and named the same forces: "ongoing softness in our contracted revenue base," "more cautious budget allocations, shorter contract durations," driven by "Most Favored Nation pricing dynamics and other macroeconomic factors" [9] [10]. Doximity's own commentary points to the identical mechanism — shorter contract durations and less budget visibility, which an analyst on the call flagged as "a theme with some others that have reported" [11] — and adds that where dollars do free up, brand managers now want either innovation or low-cost options [12]. Definitive Healthcare's outright revenue decline says the same thing from a third vantage point. When three independent companies selling into pharmaceutical commercial budgets all soften at once and cite the same drug-pricing-policy shock, the simplest reading is a cyclical air pocket in the buyers' budgets, not the erosion of any one seller's position.

Two facts sit on the other side of that read. First, the aggregate pharmaceutical digital-advertising market is not shrinking — industry trackers put 2026 healthcare digital ad spend around $26 billion and growing, with digital overtaking linear television — even as certain HCP channels such as digital display and social see usage pull back. A market that is growing in total while Doximity's growth falls to 4% is consistent with either a temporary budget freeze or a slow loss of share; the aggregate figure alone does not decide it. Second, and more telling, is what Doximity says about its own base: engagement is "at record levels," and revenue and engagement are each "up more than 50%" versus three years ago [13]. Rising engagement alongside falling revenue growth is the fingerprint of a demand-side problem — buyers pulling back — rather than a supply-side one where the audience itself is leaving.

Where the moat is genuinely tested

The durable threat is not the incumbents Doximity has already out-executed — Medscape and WebMD on the marketing side, the staffing firms on hiring, Zoom, Microsoft Teams, Teladoc and American Well on workflow, all of which it names and none of which has dented its economics [14]. It is the AI-native entrants the same filing lists almost in passing: "newer companies like OpenEvidence," and, on the clinical-tools side, Abridge, OpenAI and Anthropic [15].

OpenEvidence is the one to watch, because it attacks the moat at its root — physician attention — and monetizes it the same way Doximity does. It is a clinical-answer tool that, by outside accounts, roughly 65% of U.S. physicians now use, and it sells pharmaceutical advertising against those queries; research firm Sacra estimates it reached about $150 million of annualized revenue in 2025, up from under $10 million a year earlier, and it raised capital in January 2026 at a reported $12 billion valuation — nearly three times Doximity's current market value (CNBC; Sacra). If a rival can assemble comparable physician reach in a few years and rent it to the same drug makers, the premise that Doximity's audience "would be highly challenging and time-consuming to replicate" weakens.

The counter-case is specific, not reassuring boilerplate. OpenEvidence is a point-of-answer decision-support product, not a professional network with profiles, messaging, hiring, scheduling and telehealth woven into a physician's week; the switching cost that matters is the workflow embedment, and there Doximity is far ahead — its Clinical AI Suite has been reviewed and adopted by more than 140 health systems through their privacy and AI-governance committees, an enterprise trust that takes years to earn [16]. Doximity is also building on the same ground rather than ceding it, with its own clinical assistant, Ask (formerly DoxGPT), and a commercial "AI Search" advertising product launched in late April 2026 [17]. But this is the front on which the moat is contested, and it did not exist at scale two years ago.

The read, and what would change it

The measured conclusion is a wide moat on the supply side — the physician audience and the economics it produces — meeting a demand side that is cyclically soft today and structurally uncertain tomorrow. The evidence that the current slowdown is the pharmaceutical-advertising cycle rather than Doximity's decline is reasonably strong: three unrelated peers soften together, cite the same policy shock, and Doximity's own engagement keeps rising while its revenue growth falls. The strongest fact against a fully cyclical read is that the aggregate market is still growing even as Doximity's growth collapses to 4%, and that a well-funded, AI-native competitor is now reaching physicians at a pace no prior rival managed.

What would change the read, in either direction, is observable. If net revenue retention — which has fallen to 109% [18] — stabilizes and then turns up as policy uncertainty clears, the cyclical case is confirmed and the moat holds. If engagement or retention keeps sliding while competitors' physician reach and pharmaceutical-ad revenue climb, the structural case gains, and the 4% guide starts to look like a rate rather than a trough. Those two lines — Doximity's retention and engagement against the AI entrants' scale — are the ones worth watching over the next several quarters.

---

Founder Control

Doximity is a founder-controlled company. Jeff Tangney owns 28.9% of the economics but commands 76.3% of the votes through a ten-to-one super-voting Class B share; directors and officers together hold 31.3% of the stock and 80.3% of the votes [1]. A classified board and supermajority charter provisions entrench that control. Two facts cut the other way: the founder has not sold a share on the open market, and the whole structure sunsets to one-share-one-vote in 2031.

For a reader whose exclusion list bars weak governance, this chapter is the gate the rest of the case has to clear.

The wedge between ownership and votes

Source: 2025 Proxy Statement, beneficial-ownership table (as of June 11, 2025) [2].

Doximity carries two classes of stock. Class A, the listed shares, carries one vote; Class B, held by insiders, carries ten [3]. That ratio is the entire story of the ownership-versus-control gap. Tangney's 28.9% economic interest is real money — roughly $1.1 billion at the mid-2026 price, even after the shares fell about 70% — but it buys him 76.3% of the vote [4].

Source: 2025 Proxy Statement, beneficial-ownership table [5].

The three large index managers — FMR, Vanguard, BlackRock — together own roughly a quarter of the economics and cast under 6% of the votes [6]. Outside holders supply most of the capital and hold almost none of the control. As of March 31, 2026 the Class B block controlled approximately 79% of the combined voting power [7], consistent with 132.2 million Class A and 50.9 million Class B shares outstanding [8].

Control has concentrated, not loosened

The more revealing fact is the direction of travel. At the June 2021 IPO, executive officers, directors and their affiliates owned 52.4% of the shares and 59.3% of the votes [9]. Four years later their economic stake had fallen to 31.3% while their share of the votes had risen to 80.3% [10]. Ownership and control moved in opposite directions.

Sources: IPO Prospectus, concentration of ownership [11]; 2025 Proxy Statement, beneficial-ownership table [12].

The mechanism is written into the charter. When a Class B holder transfers shares, they convert to Class A and lose the extra votes [13]. Early venture backers — Emergence Capital, T. Rowe Price, InterWest and others — have steadily sold and converted since 2021, and every conversion lifts the relative weight of the votes that remain. Doximity's own filing states the effect plainly: conversion "will have the effect, over time, of increasing the relative voting power of those holders of Class B common stock who retain their shares" [14]. The buyback works the same way: the completed $500 million program retired only Class A shares [15], shrinking the low-vote float against a fixed high-vote block. Both forces push control toward the founder.

The entrenchment toolkit

Super-voting stock is reinforced by a standard set of anti-takeover provisions. The board is divided into three staggered classes, so only one-third stands for election each year and no single meeting can replace it [16]. Amending key charter or bylaw provisions requires two-thirds of the voting power — a threshold only the Class B block can clear or block [17].

Sources: FY2026 Annual Report, anti-takeover provisions [18] and Section 203 [19]; 2025 Proxy Statement, classified board [20] and board leadership structure [21].

Tangney chairs the board he leads as CEO, and the proxy discloses no lead independent director; the company defends the combined role as giving "a single, clear chain of command" [22]. For an outside holder, the practical consequence of the full toolkit is the same: there is no mechanism to force a change of control, a board refresh, or a sale at a premium against the founder's wishes.

What cuts the other way

Three facts keep this short of the misalignment pattern that usually earns a governance red flag.

First, the structure expires. Every Class B share converts automatically to a single class of one-vote stock on the earlier of ten years from the June 25, 2021 prospectus — i.e. June 25, 2031 — or the day holders of two-thirds of Class B elect to convert [23]. Super-voting control is bounded, not permanent; it has roughly five years left.

Second, the board around the founder is independent. Five of six directors are independent, and the audit, compensation, and nominating committees are composed entirely of independent members [24], Corporate Governance — classified board — p.15"). With majority voting control, Doximity could claim NYSE "controlled company" exemptions and drop that independence; it does not.

Third, and most telling for alignment, the founder is not selling. Across roughly 150 insider transactions filed since mid-2025, Tangney's only dispositions were shares withheld to cover tax on vesting RSUs; he has sold nothing on the open market. Total insider open-market sales over the twelve months to June 2026 came to about $9.8 million — routine, pre-scheduled 10b5-1 diversification by non-founder directors and the CFO, against a founder stake worth over a billion dollars.

Source: SEC Form 4 filings, June 2025–June 2026, as reported.

The founder also does what this reader looks for in a founder: he personally opens and answers questions on every quarterly earnings call, most recently the May 2026 fiscal fourth-quarter call [25].

Reading the red flag

The evidence points to founder control that is entrenched but aligned, not the value-destroying pattern the governance screen is built to catch. The alignment case rests on three legs: a founder economic stake of roughly $1.1 billion, no open-market founder selling through a 70% drawdown, and a majority-independent board the company is not required to keep. The entrenchment is real but bounded — control collapses to one-share-one-vote in 2031.

The strongest fact against a clean read is that outside holders have no lever until then. A classified board plus a two-thirds supermajority plus 80% insider votes means minority shareholders cannot force a board change, a strategy shift, or a premium sale for the next five years, and the mechanics of conversion and buybacks are tightening the founder's grip in the meantime. Compensation sits alongside that: Tangney's fiscal 2025 pay was $17.2 million, almost all equity, about 75 times the median employee [26] [27] — new stock that keeps flowing to a man who already controls the company.

What would move this from amber to red: material open-market selling by Tangney, any move to weaken or extend the 2031 sunset, erosion of committee independence, or related-party dealing with the controlling holder. None of those is present today. What would move it to green is mechanical — the arrival of one-share-one-vote in 2031 — provided the alignment holds until then.

---

Market Trajectory

The market Doximity sells into is not a rising tide. The company's own addressable-market estimate has stood at $18.5 billion since the 2021 IPO — unrevised through May 2026 — and it has captured only about 3.5% of it. The analog-to-digital advertising shift that once drove 40%-plus growth has cooled to mid-single-digit budget growth, and a fiscal-2028 revenue target of $1 billion management set in 2023 is now out of reach. Whether this stays a maturing niche or re-expands turns on AI-era clinical tools.

A market estimate frozen for five years

At its June 2021 IPO, Doximity sized its total addressable market at approximately $18.5 billion — $7.3 billion in U.S. pharmaceutical marketing to medical professionals, $6.9 billion in health-system marketing and staffing, and $4.3 billion in software telehealth [1]. Five years and five investor decks later, the number is unchanged: the May 2026 earnings presentation carries the same $7.3B / $6.9B / $4.3B breakdown and the same $18.5 billion total, under a slide still headed "Large & Growing Total Addressable Market" [2].

Sources: TAM from FY2026 investor deck [3]; penetration derived from FY2026 revenue of $644.9M [4]; FY2027 market-growth view from the Q4 FY2026 call [5].

Source: identical breakdown in the June 2021 prospectus [6] and the May 2026 investor deck [7].

A static market estimate carries two readings. On $644.9 million of FY2026 revenue [8], Doximity sits at roughly 3.5% of a $18.5 billion pool, which leaves a long nominal runway. But runway on a pool that has not grown in five years is a share-gain story, not a rising-tide one — and Doximity's own 10-K cautions that its market-opportunity estimates "may prove to be inaccurate" and that its business "may not grow at similar rates, or at all" even if the market does [9]. The size of the pond is not the question; how fast it is filling is.

The digital shift that already happened

Doximity's early growth rode one force: pharmaceutical and health-system budgets moving from print, in-person detailing and journals to digital channels. That shift is now largely behind the industry. Before the pandemic, management estimates pharma spent about 17% of its budget digitally; the pandemic drove digital budget growth of "roughly 30% to 40% a year"; and the post-pandemic period brought what the CFO called "a little bit of a digital detox," with budget growth settling into the mid-single digits [10]. The IPO thesis leaned on an IDC forecast that the U.S. healthcare and pharma industry would spend 38% of its advertising on digital by 2025 [11]; by 2026, industry trackers put healthcare and pharma digital at roughly 72% of the sector's media ad spend, overtaking linear TV. The transition the IPO priced as ahead of the company has mostly occurred.

Sources: pre-pandemic 17% per the Q2 FY2025 call [12]; the 38%-by-2025 IDC forecast from the IPO prospectus [13]; 2026 digital share per eMarketer industry data (not a filing).

What remains un-digitized is where the residual runway sits. Doximity's $7.3 billion pharma-marketing estimate deliberately excludes the roughly $16 billion pharma spends on physical drug samples and the direct-to-consumer budget, which the company says "may become addressable in the future if those dollars shift to physician marketing" [14]. Management's bull case is that professional promotion — details, meetings, samples — is "still very under indexed digitally," and that the medium-to-longer-term growth rate should exceed today's mid-single digits [15]. The counter is that broad healthcare advertising is already ~72% digital; the easy conversion has happened, and the remaining migration involves the stickiest analog budgets.

The growth rate has stepped down, not paused

Track the pharma HCP digital market-growth number management has cited and the deceleration is steady rather than a single cyclical dip. In August 2023 the company reported that digital pharma had grown at "half the low teens growth rate that we and e-marketer predicted," blamed a slowdown in pharma's shift to digital, and judged the market had "overcorrected this year to single-digit market growth" [16]. A year later it framed budget growth as mid-single digits [17]. By May 2025 it expected the market "to grow at roughly 5% to 7% again this year," prudently assuming the lower end [18]. By May 2026 it described near-term HCP digital pharma demand as "soft" with limited visibility, and guided its own FY2027 revenue to about 4% growth [19].

Source: midpoints of management's cited ranges across the FY2024–FY2027 earnings calls [20], [21], [22], [23].

The synchronized peer softness examined in Moat and Rivals argues part of this is cyclical — a pharma budget freeze on drug-pricing-policy uncertainty. But a step-down that has held for three consecutive years, against a market estimate that has not grown, is harder to read as purely cyclical. Management still insists mid-single-digit growth is not the long-run rate [24]; the burden of proof for a sunrise-sector view sits on that claim.

A billion-dollar target, receding

The clearest measure of how the industry narrative has moved is management's own outlook. On the August 2023 call, alongside a $460 million FY2024 revenue guide, the company said it continued "to see long-term growth rates north of 20% on our path to greater than $1 billion in revenue in fiscal 2028" [25]. Revenue reached $644.9 million in FY2026 [26], and the FY2027 guide of $664–676 million implies about 4% growth [27]. Reaching $1 billion the following year would require roughly 48% growth in FY2028 — against a mid-single-digit market. The target is no longer a plausible base case; the "north of 20%" long-term framing has not survived contact with the market.

Sources: revenue FY2022–FY2026 from the FY2026 10-K [28]; FY2027 guide midpoint and the former $1B FY2028 target from the FY2027 and FY2024 calls respectively [29], [30].

Where genuine growth still lives

Two parts of the sector are unambiguously fast-growing. Software telehealth — one of Doximity's three TAM buckets — is an independent market that trackers size in the $50–65 billion range and see compounding above 20% a year into the next decade. But Doximity's telehealth is a free workflow tool (Dialer) inside its physician offering, not a monetized growth engine, so the sector's fastest-growing slice is not where Doximity earns. The second is clinical AI. The FY2026 10-K now leads with "AI-powered tools specifically built for medicine" and a Clinical AI Suite spanning "patient communication to documentation to answering clinical questions" [31], and management says it is in "the early innings of realizing AI's full potential," with AI usage outgrowing overall workflow engagement [32], [33].

Clinical AI is the one credible route to re-expanding a frozen TAM — a genuinely new pool of clinical decision-support and point-of-care engagement that the $18.5 billion estimate does not capture. It is also the vector along which an AI-native rival is scaling into the same pharma budgets, as Moat and Rivals sets out. The same force that could enlarge the market could redistribute it. As of now the AI ramp shows up as a cost — the step-up in compute that pulls the FY2027 adjusted EBITDA margin to 49% from 55% — with the commercial return described as "potential ahead" rather than realized [34].

Reading the trajectory

On the evidence, Doximity's core market reads as a maturing niche with share-gain upside rather than a rising-tide sunrise sector. Its stated addressable market has not grown in five years; the digital-advertising shift that powered early hypergrowth is largely spent; the market-growth rate has stepped down for three straight years; and the $1 billion revenue target that embodied the old growth narrative has receded out of reach. The offsetting facts are real and worth weighting: penetration is only ~3.5%, so the company can grow well ahead of a flat market by taking share, as it did through FY2025 (Platform and Price); management argues the long-run rate is higher than today's; and telehealth and clinical AI are fast-growing adjacencies.

The read would change with evidence that the HCP digital pharma market re-accelerates above high-single digits, or that the Clinical AI Suite begins converting engagement into a materially larger monetizable pool. The most direct tell would be simple: an addressable-market number that finally moves off $18.5 billion. Until then, the industry backdrop supports a share-gains-in-a-flat-pool thesis, not the sunrise-sector premise a rising-tide case would need.

---

What the price pays for

At about $21.77, Doximity trades near 10x enterprise value to reported free cash flow — a multiple that reads as cheap for a debt-free, 89%-gross-margin franchise. The number rests on a free-cash-flow figure that adds back $121.6 million of stock-based compensation, an expense that nearly doubled in fiscal 2026 and now runs at 19% of revenue [1]. Charge that cost and the multiple moves to roughly 16x, and the price implies little more than the ~4% growth management has already guided. The margin of safety is real but sits in the balance sheet and the buyback, not in the headline multiple.

Owner FCF = reported free cash flow less stock-based compensation. GAAP P/E on FY2026; forward P/E on FY2027 consensus adjusted EPS. Sources: FY2026 10-K [2]; consensus estimates, July 2026.

Market cap uses 183.1 million Class A + Class B shares outstanding at the July 10, 2026 close of $21.77; net cash is $748.6 million with no debt. Sources: FY2026 10-K, liquidity [3]; Q4 FY2026 call [4]; share count per FY2026 10-K [5].

The company is a cash compounder with no leverage, so free cash flow is the right lens and net cash is a genuine offset to the market value (Platform and Price laid out the seven-year record). The question a value buyer has to settle is what quality of free cash flow the multiple is built on, and how much growth the price is asking to be paid for.

The stock-based compensation wedge

Doximity's reported free cash flow reached $326.5 million in fiscal 2026, up 19% year on year, because free cash flow adds back stock-based compensation as a non-cash item. That add-back is no longer small. Total stock-based compensation was $121.6 million in fiscal 2026, up from $72.4 million a year earlier and $51.1 million two years before — a rise driven mostly by research and development, where the AI-team build pushed the charge from $19.4 million to $46.2 million in a single year [6].

Subtract that cost from free cash flow and the picture changes. Post-compensation "owner" free cash flow was $204.8 million in fiscal 2026 against $200.9 million in fiscal 2025 — growth of about 2%, against the 19% the reported line shows.

Owner FCF = reported free cash flow less total stock-based compensation. Source: FY2026 10-K, cash-flow add-back and SBC schedule [7].

The same wedge explains a margin fact that the adjusted numbers hide. Adjusted EBITDA margin held at 55% in both fiscal 2025 and fiscal 2026, because adjusted EBITDA excludes stock-based compensation entirely — the $121.6 million charge is its single largest add-back, larger than depreciation, taxes and every other adjustment combined [8]. On a GAAP basis, operating income actually fell, from $227.8 million to $214.9 million, and the operating margin dropped from 39.9% to 33.3% even as revenue grew 13% [9]. Net income margin fell from 39% to 30% [10].

The gap between the two lines is mostly stock-based compensation, which adjusted EBITDA excludes. Sources: FY2026 10-K results of operations [11] and non-GAAP reconciliation [12].

That the compensation is paid in stock rather than cash does not make it free: it dilutes shareholders unless bought back. Doximity is buying it back, and then some. The company repurchased $432 million of stock in fiscal 2026, up from $116 million the year before, yet diluted share count fell only about 1%, from 201.2 million to 199.0 million [13]. A meaningful part of the buyback is running to stand still against the compensation it offsets — which is the honest way to read "we expect dilution from these new awards to be more than offset by our share repurchases," and management's own guidance that compensation rises to the low-20s percent of revenue in fiscal 2027 before trending down [14].

What the price implies

A reverse discounted-cash-flow makes the embedded expectation explicit. At an enterprise value of about $3.24 billion and a 10% discount rate, the price implies perpetual growth of roughly 0% on reported free cash flow, or about 3.5% on post-compensation owner free cash flow. In other words, the market is paying for continuation of the ~4% growth Doximity has already guided — and no cyclical recovery beyond it [15].

That framing squares the two multiples. On reported free cash flow the stock looks cheap (about 10x) because the denominator is generous; on owner free cash flow it looks fair (about 16x) for a business the market expects to grow low-single digits. Consensus lands in the same place: analysts model fiscal 2027 revenue of $670 million (about 4% growth) and adjusted earnings of $1.43 per share, putting the forward multiple on adjusted earnings near 15x, with a mean price target of $24.53 against the $21.77 price.

FY2027–FY2028 bars are consensus means (about 4% and 6% growth); FY2026 is actual. Source: consensus estimates as of July 2026; FY2026 actual per Q4 FY2026 call [16].

The valuation is not demanding on any measure — it is a low-teens-to-low-20s multiple on a highly profitable, net-cash business. What it is not is a distressed price that only makes sense if the slowdown reverses. Whichever free-cash-flow figure a buyer uses, the guided low-single-digit growth is roughly what the price already reflects. Market Trajectory argued the core market reads closer to a maturing niche than a cyclical trough; if that read is right, the stock is priced about where it should be, and the upside is optionality rather than mispricing.

Where the margin of safety sits

The scenarios below hold the model simple: they value post-compensation owner free cash flow of about $205 million under three growth-and-discount assumptions, add net cash of $748.6 million, and divide by 183.1 million shares. They are illustrative, and the result is most sensitive to the discount rate — the assumption over which a maturing-niche bear (who would demand a higher rate for AI-disruption risk) and a franchise bull most disagree.

Illustrative Gordon-growth valuations of ~$205M owner FCF plus $748.6M net cash over 183.1M shares. Source: derived from reported financials, FY2026 10-K [17].

The distribution is asymmetric, and the asymmetry is the case. Three things cushion the downside. First, net cash of $748.6 million is about $4.09 per share, roughly 19% of the price, and carries no offsetting debt [18]. Second, the $493 million left on the buyback authorization equals about 12% of the shares at today's price — and repurchases at roughly 16x owner free cash flow add per-share value in a way the fiscal 2026 program, executed partly at $45–73, did not [19]. Third, any monetization of AI Search — which management frames as a multibillion-dollar new addressable market and began selling in late April — is upside the price does not pay for [20].

The strongest fact against the read is that the bear case is not far-fetched: the same rising compensation that hollows out reported free cash flow reflects a real, ongoing AI investment cycle, and if a well-funded AI-native rival takes physician engagement and pharma budgets (Moat and Rivals), owner free cash flow could stall or fall rather than grow, and the multiple would compress rather than hold. What would settle it is observable and near-term: whether owner free cash flow — reported free cash flow less stock-based compensation — resumes growing once compensation trends back down from fiscal 2028, or whether the buyback is merely offsetting dilution while the underlying cash economics flatten. A buyer is paid to wait for that answer by a net-cash floor and an accretive buyback; a buyer is not paid for a recovery that has not yet appeared in the numbers.

---

The AI Contest

Doximity is spending its operating margin to turn a physician-engagement lead into a new pharma AI-search market. Research and development rose 40% to $130.7 million and operating margin fell to 33% from 40% in fiscal 2026 [1], ahead of AI revenue management calls minimal this year [2]. The AI-native rival it must beat, OpenEvidence, is litigating against it over data access [3], and the engagement metrics that evidence the bet are the ones the SEC is pressing Doximity to define [4].

Whether this bet re-expands the pool the growth case needs, or the contest for the same clinical AI audience simply redistributes it, is the swing factor behind the report's central question. This chapter weighs what is spent, what is shown, who is fighting, and how much of it can yet be checked.

The investment year

Management labeled fiscal 2026 its "AI investment year," and the label is literal in the accounts [5]. Research and development spending rose to $130.7 million from $93.0 million a year earlier and $82.0 million the year before — a 40% jump that lifted research and development to 20.3% of revenue from 16.3% [6]. The 380-person engineering team is, in the CEO's words, "all in to win" the race to build the best clinical Scribe and Search for doctors [7].

The spending shows up as a margin the company chose to give back. Operating income fell to $214.9 million from $227.8 million and operating margin dropped to 33.3% from 39.9%, even as revenue grew 13% [8]. Gross margin slipped to a full-year non-GAAP 91% from 92%, and to 89% in the fourth quarter, on a steep ramp in AI compute that is "outgrowing overall workflow engagement" [9].

Source: derived from reported financials, FY2022–FY2026 10-Ks; research and development and operating income per the Consolidated Statements of Operations [10].

The trade continues into the current year by design. Fiscal 2027 guidance carries adjusted EBITDA margin down to 49% from 55%, and stock-based compensation up to the low 20s as a percent of revenue before trending back down from fiscal 2028, largely the Pathway acquisition and performance grants for the growing AI team [11]. Against that spend, the return is deferred: management has forecast "minimal AI revenue contribution this fiscal year," describing a "nascent and regulated market" in which it has closed only its "first few AI search deals" [12]. The prize it is spending toward is a claim, not yet a line item — AI Search alone as "a multibillion-dollar new TAM on top of the existing pharma marketing budgets we serve today," unlocked by the $63 million paid for Pathway AI [13].

What the engagement data shows

The evidence Doximity offers that the bet is working is a set of usage metrics. Benchmark workflow engagement reached over 800,000 unique quarterly active prescribers in the fourth quarter, up roughly 30% year on year — a marked acceleration from the high-single-digit growth of a year earlier — and nearly half of those prescribers used the company's AI tools in the quarter [14]. In the nine months after the Pathway deal, AI Search and Scribe active users tripled, and last month those users averaged 31 queries each, nearly double January's rate [15].

Source: Q4 FY2026 earnings call, May 13 2026 [16]; health-system count corroborated in the FY2026 10-K [17].

The enterprise adoption is the more durable of the signals, because it clears a bar competitors cannot buy their way past quickly. As of the fourth quarter, 140 health systems had purchased the Clinical AI Suite — including 7 of the top 20 hospitals — and over 250,000 prescribers had access to it in a single hospital-approved, HIPAA-compliant workflow [18]. Each of those adoptions passed a hospital's privacy and AI-governance committees, an approval the 10-K frames as "enterprise-grade trust" that takes years to earn [19]. On the monetization side, the first proof points are thin but pointed: the AI Search product launched at a pharma client summit attended by 40 marketing leaders from the largest drug makers, and the company reported closing its first deals with top-20 pharma manufacturers [20].

One benchmark the company cites points straight at the contest. In a side-by-side clinical-search evaluation, 4,700 physician residents preferred Doximity's AI answers over those of its "nearest competitor" by two to one [21]. The competitor goes unnamed, but the identity is not much in doubt.

The rival in court

The rivalry with OpenEvidence — the AI-native clinical-answer tool that reaches physicians and sells pharma advertising the same way Doximity does, set out in Moat and Rivals — is not an abstract market share contest. The two are in active litigation. On June 20, 2025, OpenEvidence sued Doximity, its Chief Technology Officer, and its Director of AI Products in the U.S. District Court for the District of Massachusetts [22].

The subject of the fight is the raw material of clinical AI. In an amended complaint filed in October 2025, OpenEvidence added Doximity's Pathway Medical subsidiary as a defendant and alleged the defendants "gained unauthorized access to its AI medical information platform," asserting claims under the Computer Fraud and Abuse Act, breach of contract, unjust enrichment, and trespass to chattels, and seeking a permanent injunction, actual damages, and disgorgement of the defendants' profits [23]. Doximity has counterclaimed, asserting false advertising under the Lanham Act, Massachusetts consumer-protection law, and common-law defamation [24].

The case is proceeding, not settling. On January 22, 2026, the court dismissed OpenEvidence's trespass-to-chattels claim and two of Doximity's counterclaims, but denied the motions to dismiss "as to all other claims, including all counterclaims" [25]. The company states it "is currently unable to predict the outcome" or estimate any loss [26]. For a reader, the injunction request is the tail risk worth pricing: a bar on Pathway or Ask accessing a rival's data would land directly on the product the "investment year" is funding, and the litigation is a reminder that the physician-query data underpinning clinical AI is contested territory, not settled ground.

Doximity is also staffing the contest from its rival's ranks. Alongside a new CFO drawn from LinkedIn, Atlassian, and DocuSign, it hired Dr. Steve Zatz — who spent 20 years at WebMD Medscape, the last seven as its President and CEO — as President [27]. Recruiting the former chief of the incumbent physician-media franchise to run the company as it pivots to an AI platform is a costly signal that the pivot is the priority, not a side project.

How much of this is verifiable

The traction case rests almost entirely on engagement metrics — active prescribers, query counts, user-growth multiples — because the AI revenue that would settle the argument is, by the company's own guidance, minimal this year and is not disclosed as a separate line [28]. That places unusual weight on metrics that are, at present, defined by management and disclosed selectively on calls. Two facts on the record argue for weighting them with a caveat rather than at face value.

First, the SEC is actively pressing on exactly these disclosures. In a comment letter dated February 23, 2026, the Division of Corporation Finance asked Doximity to define what counts as "use" of its clinical workflow tools, to define and quantify the active-user metrics referenced on earnings calls but absent from its management discussion and analysis, to clarify whether its "over 80% of U.S. physicians" claim reflects verified active users or a broader base, and to disaggregate revenue by module — Newsfeed, Workflow, and Peer — noting the information "appears" to be "readily available" and used internally to run the business [29], [30].

Source: SEC Division of Corporation Finance comment letter to Doximity, February 23 2026 [31], [32].

Second, the metric family at issue has already been litigated. In December 2025 Doximity agreed to settle a securities class action — covering purchasers between June 2021 and August 2023 and centered on "disclosures regarding user count and engagement rates" — for $31 million, an amount fully covered by insurance and carrying no admission of liability, with a final approval hearing set for June 10, 2026 [33]. Six related derivative suits remain outstanding [34]. None of this establishes that today's AI engagement figures are wrong — the settlement was insurance-funded and admitted nothing. It does mean the AI story is being told in precisely the currency — user counts and engagement — that a class action has already contested and that the SEC now wants pinned to a definition.

The read

The AI push is real, self-funded, and a credible option on re-expanding a market that has otherwise stopped growing (Market Trajectory). The company is spending a visible margin — 40% more research and development, six points of operating margin — from a net-cash balance sheet it does not need to protect, and the enterprise adoption of 140 health systems is a genuine, hard-to-replicate asset. The evidence for it, though, is one-sided in a specific way: strong on usage, silent on revenue, and reliant on metrics under simultaneous review by a regulator and a court. The bull and bear split cleanly here — the same 800,000 prescribers are either the leading edge of a new pharma-search franchise or an audience a litigious, comparably-sized rival can rent to the same drug makers.

Three developments would move the read, and each is checkable. AI Search revenue actually appearing — management guides a back-half fiscal 2027 ramp — and, better still, becoming visible in a disaggregated revenue disclosure, would convert engagement into proof. The SEC comments resolving with defined, quantified user metrics in the management discussion and analysis would remove the disclosure caveat. And the OpenEvidence suit resolving without an injunction touching Pathway or Ask would retire the litigation tail. Until those land, the AI contest is best held as an option the price does not pay for (Margin of Safety), not as a growth engine already earning its keep.

---

Capital Allocation

Doximity returns surplus cash one way — buybacks. It has spent roughly $921 million repurchasing stock since the 2021 IPO, paid no dividend, made almost no capital expenditure, and closed one small acquisition, all funded from cash flow with no debt. The structure is disciplined; the timing is uneven. Its largest program, $500 million at a $43 average, was spent into the 2025 peak weeks before the shares fell to about $22. And a rising stock-based-pay bill means gross spend buys only a modest net reduction in the share count.

One lever, self-funded

With near-zero capital intensity and no dividend, Doximity's only real capital-allocation decisions are how much of its cash to return through buybacks and how much to hold. Cumulative repurchases since fiscal 2022 total about $921 million, every dollar drawn from operating cash flow — the company carries no debt and still ended fiscal 2026 with $748.6 million of cash and marketable securities [1]. It has never declared a dividend and does not intend to [2]. The retained cash is not idle: it earned $35.1 million of other income in fiscal 2026 [3], almost entirely interest on cash and securities [4] — roughly a 4.7% yield on the balance and about 18% of net income.

Sources: cumulative buybacks derived from Consolidated Statements of Cash Flows, FY2022–FY2026 10-Ks [5]; net cash [6]; dividend policy [7]; interest income [8].

Repurchases have run every year, scaling with cash generation. They stepped up sharply in fiscal 2026, when the $431.7 million spent was nearly half of everything the company has ever returned [9].

Source: Repurchase of common stock, Consolidated Statements of Cash Flows, FY2022–FY2026 10-Ks [10].

The timing: trough, then peak, then trough

Read against the share price, the record splits into three phases. The first, from the IPO through early 2024, bought the post-IPO trough: successive programs authorizing $410 million retired 16.5 million shares, completed by April 2024 [11], at a blended cost near $25 a share while the stock traded between roughly $23 and $36. The earliest tranche, $340 million for 13.8 million shares, was complete by October 2023 [12]. Those were well-timed purchases.

The second phase is where the money went out. The $500 million program authorized in May 2024 was completed in full, retiring 11,591,950 shares [13] — a blended $43.13 a share. Only $76.0 million of it had been spent by March 2025 (1.9 million shares) [14]; the remaining $424 million was spent through fiscal 2026, at roughly $44 a share, as the stock climbed from the low $50s to a September 2025 peak above $70. Doximity was buying its most stock at its highest prices, immediately before the fiscal-2027 guidance cut sent the shares to about $22.

The third phase began in the fall. On February 3, 2026 the board authorized a fresh $500 million program; by fiscal year-end it had bought just 321,080 shares for $7.5 million — a $23.36 average — leaving $492.5 million authorized and unspent [15]. Management has reverted to buying near the trough, with most of the authorization still in reserve.

Sources: shares and program status per Stock Repurchase Program notes, FY2024–FY2026 10-Ks [16] [17]; average prices derived from disclosed spend divided by shares retired. The IPO-through-2024 average is estimated from cumulative cash-flow spend.

The $500 million program is the crux. At $43.13 a share it cost the company about twice the current price. The same $500 million deployed at $22 would have retired roughly 22.7 million shares rather than 11.6 million — about 11 million more, or 6% of the shares outstanding. That gap is the price of buying into the run-up, and it is visible only in hindsight: the stock spent the entire program period well below its 2021 high, and the collapse followed an unforeseen guidance cut, not a slow bleed the company could have front-run.

Sources: $500M program average [18]; $492.5M remaining and $7.5M spent under the Feb 2026 program [19]; FY2026 spend [20]; share price as reported.

Gross buybacks, modest net shrinkage

The buyback's effect on ownership is smaller than the headline dollars suggest, because stock-based compensation keeps refilling the share pool. That charge has nearly tripled in two years — from $47.4 million in fiscal 2024 to $72.4 million in fiscal 2025 to $121.6 million in fiscal 2026 [21]. In fiscal 2026 it equalled 28% of the $431.7 million spent on repurchases.

Sources: repurchases [22]; stock-based compensation [23].

The result is real but slow deleveraging of the share count. Diluted weighted-average shares fell from 205.7 million in fiscal 2024 to 201.2 million in fiscal 2025 to 199.0 million in fiscal 2026 [24] — a 3.3% reduction over two years against about $552 million of repurchases. Buybacks are winning the contest against dilution, but by a narrow margin: the gross-to-net gap is stock-based pay. To the extent the compensation bill keeps climbing, a growing share of each buyback dollar mops up new issuance rather than shrinking the float — the same charge that separates reported free cash flow from owner earnings (Margin of Safety). As of March 31, 2026 the company had 132,163,035 Class A and 50,896,611 Class B shares outstanding [25].

The one deal

Acquisitions have not been a use of capital in any material sense. The only transaction in the record is Pathway Medical Inc., an AI medical-knowledge platform bought in July 2025 for $36.3 million of consideration, including $26.7 million of cash, plus up to $23.9 million of restricted stock granted to retained employees vesting over five years [26]. This is an acqui-hire — technology and an engineering team folded into the clinical-AI effort — not a growth-by-M&A strategy, and its return is inseparable from the AI investment case (The AI Contest) rather than a standalone capital-allocation bet.

Reading the record

Doximity's capital allocation is well-constructed and unevenly executed. On construction it scores high: every buyback was self-funded, no debt was taken, the retained cash earns a market yield, and the float has genuinely shrunk. On execution it is mixed — the company bought its own trough twice, but committed its single largest tranche, the completed $500 million program, at a $43 average into what proved to be a cyclical peak. The strongest fact for management is what came next: it pivoted to buying at $23 and holds $492.5 million of authorization to deploy at today's depressed price [27]. Whether the multi-year record nets to accretive turns on how aggressively that reserve is spent now, near $22, rather than left to the same drift that carried the last program up to $70.

Two things would settle the read. The first is the pace of the Feb 2026 program: a large fraction of $492.5 million retired near current prices would more than offset the mistimed 2025 tranche; a trickle would signal the buyback is a dilution valve, not a conviction purchase. The second is whether net share count starts falling faster than stock-based compensation refills it — the point at which repurchases stop merely absorbing issuance and begin compounding per-share value for the owners who stay.

---

What to Watch

The earlier chapters left a company that is easy to describe and hard to price: a near-saturated physician network converting roughly half its revenue to cash, guided to about 4% growth, and trading as though that rate is permanent. Whether the guide is a cyclical trough or a structural ceiling will not be settled by argument. It will be settled by a handful of dated disclosures over the next four to eight quarters. This chapter sets out the facts both readings share and the checkpoints that separate them.

The guide the price is built on

Doximity's own fiscal-2027 outlook is the anchor. Management guided full-year revenue of $664 million to $676 million — about 4% growth at the midpoint — with an adjusted EBITDA margin of 49%, down from 55%, as AI-compute spending continues [1]. It framed HCP digital pharma-ad demand as soft with limited visibility, market growth "at or below 5%," and 65% of subscription revenue booked at guidance — in line with its three-year average [2]. Net revenue retention, the metric most directly tied to that growth rate, was 109% in fiscal 2026, down from 119% and 114% in the two prior years [3].

Sources: Q4 FY2026 earnings call, outlook [4]; FY2026 10-K, MD&A metrics [5].

The same facts, read two ways

The bull and the bear are not working from different numbers. They read the same disclosures in opposite directions. Setting the two readings side by side is the honest way to see where the disagreement actually lives — and it lives almost entirely in whether the deceleration is temporary.

Sources: Q4 FY2026 earnings call [6] and CEO Q&A [7]; FY2026 10-K, MD&A metrics [8] and SBC note [9]. The economics behind rows 3-5 are worked in The AI Contest and Margin of Safety.

Two facts on that table are worth separating from opinion because they are firmer than either narrative. NRR's mechanical link to the growth rate is the company's own description — it "fluctuates as that growth rate fluctuates" — so a retention rebound and a demand rebound are the same event, not two independent confirmations [10]. And the AI-Search TAM is a genuine adjacency, not the existing budget re-labelled: management places U.S. paid search near $19 billion and calls the healthcare-professional slice "incremental to the market we're in today" [11]. Both cut toward the bull, but neither is yet a number in the revenue line.

The checkpoints that separate the two

Each disagreement above resolves at a specific disclosure. The value of listing them is that most carry a date and a threshold, so the through-line's open question becomes checkable rather than rhetorical. Doximity's fiscal year ends March 31; the second half of fiscal 2027 is the October-2026 through March-2027 window, reported on the February-2027 and May-2027 calls.

Sources: Q4 FY2026 earnings call, outlook and CEO Q&A [12] [13]; FY2026 10-K, litigation note [14]; SEC comment letter, Feb 23 2026 [15].

The checkpoints do not arrive together, and the sequence matters. The SEC comment letter is the nearest: it was dated February 23, 2026, presses Doximity to define what "use" of its workflow tools means and to provide the metric for all periods, and runs on a ten-business-day response cycle — so how the engagement KPIs are revised is knowable soon, and the reliability of those KPIs is what the whole AI-traction narrative rests on [16]. Retention and booked-revenue conversion report every quarter. AI-Search revenue is a back-half fiscal-2027 event by management's own framing — it began selling in late April, expects no meaningful first-half contribution, and anticipates a more notable ramp into the fiscal back half [17]. The owner-FCF question does not clear until fiscal 2028, when stock-based compensation is guided to trend back down from the low-20s percent of revenue it reaches this year [18]. The OpenEvidence suit — now naming Doximity's Pathway Medical subsidiary and turning on Computer Fraud and Abuse Act data-access claims, with Doximity counterclaiming — has no scheduled resolution [19].

How the checkpoints map to value

The Margin of Safety chapter framed a fair-value range of roughly $15 in a structural-decline case, about $21 in a base case, and near $29 if a cyclical recovery and AI monetization arrive. The watch list is the bridge between those numbers and reality: the bear column filling out — NRR stalling, another sub-5% market year, AI Search staying minimal — pulls toward the low end, while the bull column confirming pulls toward the high end. What makes the setup asymmetric rather than merely cheap is underneath both scenarios: $749 million of net cash and a $493 million repurchase authorization that management has begun deploying near $22, against roughly $43 for the prior program [20]. That floor holds whichever way the demand question breaks; the checkpoints decide only how much sits on top of it.

None of the seven signals is decisive alone, and a reader should weight the early, mechanical ones — the SEC metric definitions, quarterly retention, booked-revenue conversion — more heavily than the slower or noisier ones, because they arrive first and are harder to narrate around. The single reading that would most cleanly favor the structural case is a second consecutive year of sub-5% market framing with NRR still at or below 109%; the reading that would most cleanly favor the cyclical case is a disaggregated, material AI-Search line landing in the fiscal back half alongside a retention turn. Until those print, the deceleration is genuinely two-sided, and the disclosures above are where the evidence will come from.

---

Disclosure Quality

Doximity's reported cash is real: operating cash flow has run 1.2 to 1.7 times net income for five straight years, and the classic forensic tests for manufactured earnings come back clean. The reliability questions sit one layer in — roughly one-seventh of pretax profit is fading treasury income, the prior-year record was flattered by a low tax rate, and the engagement metrics and module revenue that carry the growth story are, by management's own account to the SEC, undefined and unallocable.

The cash is real

The first thing a skeptic checks is whether reported profit turns into cash. Here it does, and then some. Operating cash flow was $326.5 million in fiscal 2026 against $196.1 million of net income — a 1.67x conversion — and the ratio has exceeded 1.0 in every year since fiscal 2023 [1]. The mechanism is ordinary for a subscription business: customers pay ahead of the service, so cash arrives before revenue is booked, and two large non-cash charges — $121.6 million of stock-based compensation and $14.4 million of depreciation and amortization — sit between accounting profit and cash [1]. Capital expenditure is close to zero; the company even routes its modest internal-software build through the investing line rather than capitalizing costs that belong in operating expense.

Source: FY2026 10-K, Consolidated Statements of Cash Flows and Statements of Operations [1] [2]. Fiscal 2022 net income exceeds cash flow because of a one-time $40.8 million tax benefit that year.

The supporting checks agree. Days sales outstanding has held near 82 days across fiscal 2024 to 2026, and receivables grew 12.8% in fiscal 2026 against 13.0% revenue growth — no build-up that would signal revenue booked ahead of collection [3]. Goodwill and intangibles together are 10.7% of total assets and have never been impaired, so there is no soft-asset overhang waiting to be written down. The allowance for doubtful accounts is a stable 0.9% of receivables against a customer base of large pharmaceutical manufacturers and health systems.

Source: derived from FY2026 10-K balance sheet, income statement and cash flow statement, fiscal 2024–2026 [2] [3].

That cash generation still carries the two caveats earlier chapters priced. The largest cash add-back, stock-based compensation, is a real economic cost paid to employees in shares rather than dollars; the gap between reported free cash flow and owner cash flow after that charge is the subject of Margin of Safety. And the one working-capital line worth watching turned negative this year: deferred revenue fell $8.1 million in fiscal 2026 after rising $15.2 million in fiscal 2025, which management attributes to the timing of customer billings and program launches [4]. Because deferred revenue is billings not yet recognized, a drawdown means revenue ran slightly ahead of new bookings — a modest forward-looking signal that fits the roughly 4% growth guided for fiscal 2027, not a sign of inflated current earnings.

What the headline profit contains

The reliability question that reported cash does not answer is what sits inside net income. Two items make the profit line less representative of the operating business than it looks.

The first is interest income. Doximity holds $748.6 million of cash and marketable securities, and the yield on it — $35.7 million in fiscal 2026 — is booked below the operating line as "other income" [5]. That is 14% of pretax income, up from 12% two years ago as rising rates lifted the yield. It is genuine cash, but it is a treasury return, not a return on the physician-marketing franchise, and it is set to shrink: the investment base fell 18% over the year as buybacks drew it down, and the 10-K warns that future investment income may fall short as rates ease [6].

The second is the tax rate. Fiscal 2025's $223.2 million of net income — the "record" year the current price is measured against — carried a 15.3% effective tax rate; fiscal 2026 normalized to 21.6% [2]. That single change explains more than half of the 12% drop in reported net income: pretax income fell $13.6 million while the tax provision rose $13.6 million. Operating income itself fell a milder 5.7%. Read through the mix, fiscal 2026's earnings decline overstates the operating slowdown, and fiscal 2025's peak overstates the underlying earning power — the reverse-signal a reader anchoring on the price-to-earnings multiple should carry.

Source: FY2026 10-K, MD and A Results of Operations and Note 16 [2] [5].

The non-GAAP framing management prefers cuts the opposite way. Adjusted EBITDA of $357.8 million (a 55% margin) removes the $35.1 million of other income — so it strips out the treasury tailwind — but it also adds back the $121.6 million of stock-based compensation, this year plus new $4.9 million legal and $1.6 million acquisition adjustments [7]. The reported record is honest on both counts; the point is that neither headline — GAAP net income nor adjusted EBITDA — is a clean read of operating economics on its own.

The metrics the story runs on

The financial statements are the reliable part of Doximity's disclosure. The softer part is the operating data the growth and AI narratives lean on — and here a fiscal 2026 SEC review put the questions on the record. The Division of Corporation Finance's February 23, 2026 comment letter asked Doximity to define and quantify the active-user engagement metrics its executives cite on earnings calls but that appear nowhere in the MD and A, to clarify the denominator behind the "more than 80% of U.S. physicians" claim, and to disaggregate revenue by product module — noting the module data appeared "readily available" [8] [9]. Doximity's March 23 response, and the staff's March 26 closeout, are what make the exchange informative.

Source: SEC comment letter (Feb 23, 2026) and Doximity response (Mar 23, 2026) [8] [10].

Two of the responses are the substance. On engagement, management told the staff that the active-user figures referenced on calls "do not correlate highly with its subscription revenue," were mostly cited qualitatively in response to analyst questions, and that it "does not plan on disclosing other user engagement metrics on earnings calls on a go-forward basis" [10]. That is a notable concession: the record-engagement figures offered elsewhere as evidence the platform is deepening are, by the company's own account, not a reliable proxy for the revenue they are meant to foreshadow, and they are being retired from the earnings script rather than defined and standardized. On revenue mix, management stated it "does not track or manage revenue at the individual module level, and its financial systems do not have the capability to identify or allocate revenue by module" — even though its CEO had called Newsfeed the "most monetized" product [11]. Integrated subscriptions bundle several modules under a single stand-ready obligation, so revenue is recognized at the subscription level. The consequence for an investor is concrete: there is no way from the filings to see how revenue splits across products, and no way to isolate AI Search revenue as it appears — it will surface, if it does, inside the same undifferentiated Marketing Solutions line.

The counter-fact runs the other way, and it matters. This was a routine disclosure-improvement review, not an enforcement action; the staff completed it with no further comment on March 26, 2026 [13]. And the review produced real improvements: beginning with the fiscal 2026 10-K, Doximity will define its workflow-provider metric with a prior-year comparable and pin down the physician denominator — physicians under 76, holding an active license, listed on the NPI registry, who have claimed a profile [12]. Disclosure is getting better, not worse. What does not improve is module-level revenue visibility, which management has declined to provide.

Two adjacent facts round out the picture. Fiscal 2026 was the first year a single customer crossed 10% of revenue — one customer at 11%, against no customer above the threshold in fiscal 2025 or 2024 — a concentration worth tracking in a business already reliant on a small set of large pharmaceutical buyers [14] [15]. And the same metric family the SEC questioned was the subject of a securities class action over "disclosures regarding user count and engagement rates," settled in December 2025 for $31 million paid entirely by insurers with no admission of liability; six shareholder derivative suits remain outstanding, with loss not estimable — detail covered in The AI Contest [16].

The read that fits the evidence: the audited numbers Doximity reports are high quality and cash-backed, and there is no sign of manufactured earnings. The reliability gap is in the operating metrics and revenue mix that sit outside the audited statements — the very inputs the growth-and-AI case relies on — where the company has now conceded the KPIs do not track revenue and the module split cannot be produced. That does not impeach the cash; it means the story the cash is supposed to be growing into has to be taken partly on trust. The condition that would change the read is a fiscal 2027 in which a defined workflow-engagement metric moves with reported revenue, and AI Search revenue becomes visible enough to verify — the disclosures management has now promised are the place to check.